Results 191 to 200 of about 44,321 (338)

Non‐Operable Squamous Cell Carcinoma of the Infraorbital Region Treated With Electrochemotherapy: A Case Report

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Cutaneous squamous cell carcinoma (cSCC) is a malignant epithelial tumor of the skin, classified as a nonmelanoma skin cancer. It may develop from precancerous conditions such as chronic inflammatory dermatoses, actinic keratosis, or actinic cheilitis, but can also arise de novo.
Gianluca Nicolai, Francesco Campanella, Sergio Alexandre Gehrke, Antonio Scarano   +3 more
wiley   +1 more source

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. [PDF]

Blood Adv
Kowalski A, Lykon J, Diamond B, Coffey D, Kaddoura M, Maura F, Hoffman J, Pandey A, Kazandjian D, Landgren O.   +9 more
europepmc   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

Bispecific Antibodies: Strategies Available to Optimize Their Safe Delivery in Patients with Multiple Myeloma. [PDF]

Antibodies (Basel)
Giles HV, Kishore B.
europepmc   +1 more source

Bispecific antibody toxicities

Canadian Medical Association Journal
Britto, Joanne, Mian, Hira, Davies, Gwynivere A., Balitsky, Amaris K.   +3 more
openaire   +2 more sources

Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an Animal Model [PDF]

, 2006
Ursula Reusch, Magesh Sundaram, Pamela A. Davol, Sarah D. Olson, James B. Davis, Kurt Demel, Julie Nissim, Ritesh Rathore, Paul Y. Liu, Lawrence G. Lum   +9 more
openalex   +1 more source

Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Polatuzumab vedotin (Pola) is an antibody‐drug conjugate approved for the treatment of diffuse large B‐cell lymphoma (DLBCL). Several reports suggest that the tumor microenvironment influences the outcome of DLBCL treatments; with Pola, however, the link between tumor microenvironment and treatment outcome remains unclear ...
Mayu Tomita, Natsumi Kawasaki, Keigo Yorozu, Sei Shu, Chie Kato, Mitsue Kurasawa, Bansho Masutani, Nicolas Sax, Yoriko Yamashita‐Kashima, Shigeki Yoshiura   +9 more
wiley   +1 more source

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies [PDF]

Valentina Cardenas Castro, Kevin G. Shim, Mariano Arribas, Justine L. Wilson-Miller, Adrienne Nedved, Jason N. Barreto, Mustaqeem Siddiqui, Joselle Cook, Nadine Abdallah, Rahma Warsame, David Dingli, Wilson I. Gonsalves, Taxiarchis Kourelis, Morie A. Gertz, Suzanne R. Hayman, Nelson Leung, Prashant Kapoor, P. Leif Bergsagel, Udit Yadav, Julia E. Wiedmeier, Saurabh Chhabra, Sikander Ailawadhi, Ricardo Parrondo, Shaji Kumar, S. Vincent Rajkumar, Angela Dispenzieri, Yi Lin, Tyler B. Sandahl, Rafaël Fonseca   +28 more
openalex   +1 more source

Multiformat T‐Cell‐Engaging Bispecific Antibodies Targeting Human Breast Cancers [PDF]

, 2015
Yu Cao, Jun Y. Axup, S. Y. Jennifer, Rongsheng E. Wang, Seihyun Choi, Virginie Tardif, Reyna K. V. Lim, Holly Pugh, Brian R. Lawson, Gus Welzel, Stephanie A. Kazane, Ying Sun, Feng Tian, Shailaja Srinagesh, Tsotne Javahishvili, Peter G. Schultz, Chan Hyuk Kim   +16 more
openalex   +1 more source

Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

, 2023
Paul Haluska, Michael E. Menefee, Elizabeth R. Plimack, Jacob Rosenberg, Donald W. Northfelt, Theresa LaVallee, Shi Li, Xiang‐Qing Yu, Peter Burke, Jaiqi Huang, Jaye L. Viner, Jennifer McDevitt, Patricia LoRusso   +12 more
openalex   +1 more source